Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Accured Expenses (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Change in Accured Expenses data on record, last reported at $25.7 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 120.46% year-over-year to $25.7 million; the TTM value through Dec 2025 reached $42.2 million, up 120.32%, while the annual FY2025 figure was $42.2 million, 120.32% up from the prior year.
  • Change in Accured Expenses reached $25.7 million in Q4 2025 per SNDX's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $25.7 million in Q4 2025 and bottomed at -$9.2 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $4.4 million, with a median of $1.5 million recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 9304.88% in 2022, down 893.81% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $638000.0 in 2021, then skyrocketed by 1618.81% to $11.0 million in 2022, then tumbled by 31.58% to $7.5 million in 2023, then soared by 55.34% to $11.7 million in 2024, then soared by 120.46% to $25.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $25.7 million in Q4 2025, $1.1 million in Q3 2025, and $17.9 million in Q2 2025.